Connect with us

Cannabis News

GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans

Published

on

A new Senate bill is being introduced that would encourage research into the therapeutic potential of psychedelics, create a new office at the Department of Veterans Affairs (VA) to develop innovative treatments for serious mental health illnesses, and help review the scheduling status of drugs like psilocybin, ibogaine and MDMA.

The legislation, titled the “Veterans Health Administration New Therapeutics Training Act,” is sponsored by Senator Tim Sheehy (R-MT). According to bill text obtained by Marijuana Moment, it would direct the VA to take steps to ease studies on psychedelics and other emerging therapies.

This is one of the latest examples of Congressional efforts to encourage scientific research on psychedelics, focusing on military veterans with conditions such as post-traumatic stress disorder (PTSD), treatment-resistant depression, substance use disorder, traumatic brain injury (TBI), chronic pain, and more.

The bill is expected to be formally introduced on Wednesday, according to a source familiar with the planning. Marijuana Moment reached out to Sheehy’s office for comment, but a representative was not immediately available.

“Ongoing therapeutic interventions, including some psychedelic-assisted therapies, that have been evaluated by the Food and Drug Administration since the enactment of this Act could significantly change the landscape of treatment for post-traumatic stress disorder, depression, and other mental health conditions affecting veterans,” the bill finds.

“The administration of certain emerging therapies may require intensive clinical engagement, interdisciplinary teams, dedicated clinical space, structured preparation and post-treatment integration that differ significantly from traditional outpatient mental health services,” he continues, adding that the VA is “uniquely positioned to provide comprehensive veteran-centered care that combines mental health, medical health services and support into a single system.”

That’s the only explicit mention of “psychedelics” in the legislation, and it doesn’t list the specific psychedelic substances that would be prioritized for research, but that’s a common feature of recent bills on the subject, with many other examples using catchy terminology, such as innovative or novel treatments or therapies that effectively serve as “substitutes for psychedelics.”

The measure would establish a new Office of New Therapeutics under the Veterans Health Administration (VHA) to facilitate research initiatives. Studies examining alternative treatments would focus on substances such as psychedelics that are being considered for approval by the Food and Drug Administration (FDA).

“In the absence of centralized governance and implementation planning, the Department may experience delays, safety risks, or inconsistent access following regulatory approval of these therapies,” the bill’s findings section says. “Establishing a dedicated Office of New Therapeutics will enable the Department to proactively evaluate, research and implement emerging treatment modalities consistent with patient safety and evidence-based practice.”

There would be at least one “Center of Excellence” in each VA regional district to help develop a national model for the program facilitation initiative. A Veterans Advisory Board, made up of veterans, experts and health professionals, would be created to advise on issues such as access barriers and safety protocols.

VA should also coordinate with other federal agencies—including the US Department of Health and Human Services (HHS), FDA, Centers for Medicaid and Medicare Services (CMS), Department of Defense (DOD), and Drug Enforcement Administration (DEA)—to explore regulatory issues, possible rescheduling action for new therapies, and resources to provide psychiatric health care access and treatment.

The VA should provide annual reports to Congress to update lawmakers on its progress. Within 180 days of the bill’s passage, the department would have to report on practical issues, such as staffing needs and regulatory hurdles.

The bill is somewhat Similar intent to another bipartisan measure introduced earlier this monthSponsored by Senators Ruben Gallego (D-AZ) and David McCormick (R-PA), it would provide $30 million in annual funding to establish psychedelic-focused “centers of excellence” at VA facilities where veterans can receive innovative treatments involving substances such as psilocybin, MDMA and ibogaine.

Supplemental version of the house bill—Sponsored by the Chair of the Congressional Psychedelics Advancing Therapies (PATH) Caucus Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—were introduced last year, but have yet to advance in the House. The measures of the House and Senate are very similar, with minor format differences.

Lawmakers and advocates supporting those reform bills have allies in senior Trump administration positions, including VA Secretary Doug Collins and Robert F. Kennedy, Jr. Secretary of HHS, both of whom have endorsed psychedelic policy reform.

Kennedy recently told Joe Rogan on a podcast episode The administration is “very keen” to create a pathway for novel therapies and that federal agency officials want to “get the public up to speed as quickly as possible.”

Multiple veterans groups also recently advised lawmakers in Congress about the need continue to explore psychedelics and marijuana as alternative treatments At hearings on Capitol Hill for the military veteran population. The Wounded Warrior Project (WWP) and Veterans of Foreign Wars (VFW) specifically cited the Innovative Therapy Centers of Excellence Act as an example of a reform they are supporting.

Correa and Bergman, the sponsors of this legislation, submitted separately in January also to promote research into the therapeutic potential of certain psychedelics in the treatment of serious mental health conditions experienced by veterans.

January’s bipartisan pair also discussed it the importance of strategically advancing psychedelic reform in a way that mitigates bureaucratic conflict and the influence of external interests. They said even a single mistake could threaten to turn the movement upside down.

Last year, VA Secretary He proclaimed his mission to promote access to psychedelics for veterans with serious mental health conditions, it was possible to say that it “opened that door wider than most probably thought”. The department came under fire in 2024 after rejecting an organization’s grant application It helps connect veterans to programs overseas where they can receive psychedelic therapy to treat serious mental health conditions.

Meanwhile, in November, Kennedy, Vice President JD Vance, FDA Commissioner and other Trump administration officials attended the “Make America Healthy Again” summit. it was a session dedicated to studying psychedelic medicine.

In June, Kennedy said that his agency “Fully committed” to expanding research into the benefits of psychedelic therapy. and, along with the head of the FDA, aims to give military veterans legal access to these substances “within 12 months.”

The secretary also said that in April He had a “wonderful experience” with LSD at the age of 15He took it because he thought they would be able to see dinosaurs, as depicted in a comic he was a fan of.

Last October, Kennedy specifically criticized the FDA under the previous administration for the agency’s “eradication of psychedelics” and a laundry list of other issues that he said was a “war on public health” that would end under the Trump administration.

read it the text Under the Veterans Health Administration’s New Therapeutics Training Act:

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Building Nevada’s most vertically integrated cannabis operation

Published

on

By

Nevada is one of the most competitive retail cannabis markets in the United States, and Deep Roots Harvest has been betting for years that the way to win is to control everything. 11 cultivation, processing, manufacturing, extraction and retail locations all under one roof, or pretty close to it. Chris O’Ferrell, Deep Roots Harvest’s Chief Cultivator, runs the growing side of that operation in two facilities totaling 30,000 square feet, pushing 500 pounds of harvested cannabis per week and 2,000 pounds of biomass per month.

“The Source and Deep Roots harvest retail team sells 75 kilos of cannabis daily, 500 kilos weekly, over a third of which is in-house to support the High Heads, Neon Moon and CAMP brands. We cultivate, extract, process, manufacture and work the retail locations,” says Chris. “We have one of the largest market shares in Nevada in terms of retail volume and gross sales.”

That volume is produced by 60 full-time employees at the two sites, and the crop program behind it is, by any reasonable measure, built for efficiency and quality. “Many of the genetics in our library consistently exceed 100 grams per square foot, which directly helps reduce our overall cost per gram,” explains Chris. “We operate with a consumer-first approach, focusing on cost consciousness while providing tasty and competitive offerings. We operate below 70 cents per gram, a benchmark that reflects careful cost management. Getting there and staying there has required compressing costs at all input levels while continuing to invest in technology that moves the needle on quality, cost efficiency and performance.”

© Deep Roots Harvest Chris O’Ferrell, Chief Cultivator at Deep Roots Harvest

Genetics as intended by the producer
The transition of light is a clear example of this, as is the case with cannabis. In the beginning, the company used your classic HPS lights. As LED technology advanced, Deep Roots made the switch. However, it wasn’t just about improving energy efficiency. Chris and the team understood that the more precisely the crop was targeted, the better the final product would be. Energy savings don’t necessarily show up on retail shelves, but crop control does, in the form of flowers that express their genetics the way the grower intended.

To achieve this level of control, the spectrum became a critical tool. “We start with the spring setting, using the blue light to regulate the spacing of the interiors and control the spacing,” he explains. “As the plants progress, we move to the summer spectrum until the end of week eight, switching to a broader spectrum light with balanced wavelengths. This increases the red light, along with other parts of the spectrum to more closely replicate sunlight. We also increase the light intensity during the flowering phase to improve the plant’s photosynthetic performance, accumulation and photosynthetic activity. The parameters support the initiation of flowering, accelerate maturation and allow the plant to reach its potential they allow him to fully express his genetics.”

Nothing is left to chance
At canopy level, plants from the two largest facilities are housed in two-gallon coco pots, chosen to accommodate longer growing periods and larger plant structures. The second facility operates stone wool. Both use substrate sensors in connection with fertigation control, and track performance at different growth stages. Dissolved oxygen is injected into the root zone to increase availability, and a chlorine injection system keeps the lines clear of pathogens with a relatively inexpensive cleanup compared to conventional cleaning programs. “A chlorine injection system is relatively inexpensive to implement, replacing approximately $40,000 in other cleaning and disinfection products annually,” says Chris. “It’s all about being ahead of the curve.”

Pest management is entirely biological, implemented in conjunction with mechanical and cultural controls. “We haven’t had any pest problems,” says Chris. “This was also a decision based on reducing inputs while maintaining, if not improving, the quality of the product.”

Genetics is the backbone of cannabis operations and the gas that drives the company’s engine. They receive the same systematic treatment as all other parts of the operation. A steering committee reviews the portfolio quarterly, withdrawing underperforming cultivars and acquiring replacements based on market data from multiple markets, cross-referenced with gaps in the current menu. The criteria are repeatable agronomic performance, yield, potency, distinctive flavor profile and the ability to wash well for extraction, ensuring strong yields for both rosin and resin production. “All genetics need to adapt to the program,” says Chris. “Unique production, potency and flavor expression that fills the void of what we don’t have on the menu. It’s about finding a commercial cultivar that works well and fits the existing infrastructure. All the cultivars we grow now have a similar and predictable growth structure. The difference is the color, the smell, the experience. They are very close agronomically.”

For more information:
Harvest deep roots
deeprootsharvest.com

Continue Reading

Cannabis News

Marijuana Reform Group Polls Consumers About Freedoms Where They Live Ahead Of 4/20

Published

on

By

Ahead of the unofficial cannabis holiday on 4/20, a leading marijuana reform group is asking consumers to take a poll about the freedoms they experience (or lack thereof) where they live.

The new 2026 Cannabis Freedom Survey from the National Organization for Reform of Marijuana Laws (NORML) includes the questions: “Where you live, how free are adults to legally possess and access cannabis?” and “Where you live, how concerned are you about the legal consequences for cannabis users?”

The survey “is designed to capture the real-time sentiment of cannabis consumers in the United States and abroad to see how individuals experience the politics of cannabis in their daily lives,” NORML said.

The the questioning It also includes a question asking people to choose “the most important step that would increase the freedom of cannabis where you live.”

Options include ending marijuana arrests, legalizing adult marijuana, allowing adults to grow their own cannabis, allowing the sale of legal cannabis, making legal cannabis cheaper, clearing records and resolving past convictions, changing federal cannabis laws and protecting consumer rights (parental, workplace, housing, health).

In addition, it asks whether respondents at the national level fully respect marijuana policy for consumer freedom, whether it is moving in the right direction, stagnant without significant progress, or regressing.

“In some jurisdictions, cannabis comes with real freedom. In others, it still comes with real consequences,” NORML Director of Development JM Pedini said in a press release. “This survey is about capturing that gap, not just what the laws say, but how people actually experience them.”

Pedini told Marijuana Moment that the organization will likely compile the results and release them a few days before 4/20.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Governor vetoes medical cannabis bill

Published

on

By











The veto pen is one of the most powerful tools in the Mississippi Legislature, and Governor Tate Reeves has used it throughout his tenure. This year, his vetoes have mostly targeted public health bills so far, with more to come.

There are three ways Reeves could handle the bills that passed both chambers. He can sign bills he supports and allow them to become law without his signature. He can also block legislation he disagrees with by vetoing a bill or part of it and deferring it to a future legislative session.

As of Wednesday, April 8, he has vetoed four bills, half as many as in the previous two sessions, but Reeves will continue to review the legislation and reject more proposals in the coming days.

Reeves vetoed two medical marijuana bills that passed the Legislature this session, dealing a fatal blow to bills that have already faced friendly chambers. One of the bills, the “Right to Try Medical Cannabis,” contained only one specific provision that Reeves disputed. The original intent of the bill, which Reeves praised, was to expand the opportunity to try medical marijuana to those with debilitating conditions that fall outside the scope of current law.

Read more at Clarion Ledger










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media